In patients with microsatellite-stable (MSS) and O6-methylguanine-DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer (mCRC), the researchers administered two cycles of temozolomide first as an immunosensitizer, and then a combination of low-dose ipilimumab and nivolumab. This evidence concerns the gene MGMT and metastatic colorectal cancer.